ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BOLD / options
HRTX (34) RNXT (29) NMAD (31) CTOR (34) ⌘ Pro Terminal β†’

Boundless Bio Inc. (BOLD) Options Positioning, Max Pain & Unusual Sweeps

$2.44 -1.22% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.43

Boundless Bio Inc. (BOLD) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $56.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BOLD Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BOLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Boundless Bio Inc. (NASDAQ: BOLD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.44 (-1.22% 1D, market cap $56.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BOLD ranks #340 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BOLD compare to HRTX and RNXT in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLD carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M) and RNXT (RenovoRx Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $56.9M). Among the 5-stock peer group, BOLD leads on earnings multiple (N/A) while BOLD leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BOLD?
β–Ό

Per BOLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782303), Boundless Bio Inc. generated $177.9M in revenue (-13.3% YoY), -$58.2M in net income, and -$47.2M in free cash flow against $157.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.43 (-0.41%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (46/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510046
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk D+
Cash (8)Whales (10)SEC (10)Macro (13)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-5.3% Base Target
$3 Bull$2 Base$2 Bear
πŸ“¬ FREE BOLD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BOLD)Realized 20D OHLCV Swing Band: Β±11.8%
Deterministic 5-Pillar Attribution (46/100 Composite)
πŸ” WHY BOLD SCORES 46/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime Γ— Technicals: 67% of 52W Range β€’ RSI-14 at 43.9 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Whale & Options Positioning+10/20 pts (22% of score)

20D Institutional Volume Accumulation (Β±11.8% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
38
Grade E$2.43+0% Next Q
Q2 (-2Q)
41
Grade D$2.43-0.8% Next Q
Q3 (-1Q)
43
Grade D$2.41+1.2% Next Q
Current
46
Grade D$2.44-6.1% Hist 90D Ξ±
Trajectory: E (38) β†’ D (46)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a BOLD Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While BOLD currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.64) and Max Pain ($2.56) forces dealer call-delta covering toward $3.32.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BOLDβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBOLD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±11.8%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BOLD)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BOLD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BOLD)

  • βœ“Walkthrough of BOLD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BOLD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.41%πŸ“ HORIZONTAL RANGE
2026-11-04O $2.47H $2.47L $2.44C $2.44VOL 91.2K
RES: $3.60SUP: $2.16SMA50: $2.64SMA200: $1.92
$3.30$2.73$2.17$1.61$1.05RES $3.60SUP $2.16$2.442026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BOLD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BOLD Butterfly Map β†’ + Track BOLD β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -13.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BOLD today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BOLD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BOLD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BOLD)

Health Care Rank #340 of 1015 βš”οΈ HRTX vs BOLD Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BOLD vs. HRTX, RNXT, NMAD, CTOR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Boundless Bio Inc. (BOLD) ranks #340 by composite RQD confidence (46/100, grade D) and #720 by equity capitalization ($56.4M). Within this direct 5-issuer industry benchmark cohort, BOLD leads on earnings valuation at N/A trailing P/E, while BOLD leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. BOLD currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BOLD ACTIVE
Boundless Bio Inc.
D 46/100 β€” β€” -35.0% -1.22% $56.4M Benchmark Subject
HRTX
Heron Therapeutics Inc.
E 34/100 β€” 73.3% -35.0% +6.27% $56.0M /hrtx-vs-bold β†’
RNXT
RenovoRx Inc.
E 29/100 β€” 70.9% -35.0% -5.26% $56.9M /rnxt-vs-bold β†’
NMAD
Nomad Power Solutions Inc.
E 31/100 β€” β€” -35.0% -2.53% $55.9M /nmad-vs-bold β†’
CTOR
Citius Oncology Inc.
E 34/100 β€” β€” -35.0% +7.24% $55.2M /ctor-vs-bold β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001782303 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Boundless Bio Inc. (BOLD) reported GAAP revenue of $177.9M (-13.3% vs. FY2024 revenue of $205.1M , and +16.0% cumulative change since FY2023) , GAAP net income of -$58.2M, operating cash flow of -$46.7M, and free cash flow of -$47.2M (+25.5% YoY). On the balance sheet, BOLD closed FY2025 with $157.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $177.9M -$58.2M -$46.7M -$47.2M $157.1M β€”
FY2024 (FY) 2024-12-31 $205.1M -$65.4M -$60.8M -$63.4M $206.4M β€”
FY2023 (FY) 2023-12-31 $153.4M -$49.4M -$46.9M -$46.9M β€” β€”

3. BOLD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BOLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Boundless Bio Inc. (NASDAQ: BOLD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.44 (-1.22% 1D, market cap $56.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BOLD ranks #340 in composite RQD confidence.

How does BOLD compare to HRTX and RNXT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLD carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M) and RNXT (RenovoRx Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $56.9M). Among the 5-stock peer group, BOLD leads on earnings multiple (N/A) while BOLD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BOLD?

Per BOLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782303), Boundless Bio Inc. generated $177.9M in revenue (-13.3% YoY), -$58.2M in net income, and -$47.2M in free cash flow against $157.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BOLD trading relative to its 50-day, 200-day, and 52-week technical levels?

BOLD last traded at $2.44 (-1.22% on volume of 91,159 shares), positioning the stock -7.58% below its 50-day simple moving average ($2.64) and +27.08% above its 200-day simple moving average ($1.92). Across its 52-week range of $0.96 to $3.16, BOLD sits at the 67.3% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±11.8% ($2.15 to $2.73).

Direct Sub-Reports: BOLD RQD Cockpit BOLD 12M Forecast BOLD Earnings & Move BOLD Dividends & DRIP BOLD Insiders & 13F BOLD Whale Options BOLD Profit Sankey BOLD News & Why
ROARABLE RATING BRIEF β€’ RQD 46/100 (D) βœ“ SEC XBRL & RQD VERIFIED

BOLD β€” Boundless Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Boundless Bio Inc. (BOLD) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.44 (-1.22% 1D, market capitalization $56.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Boundless Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Market capitalization is $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Boundless Bio Inc. (BOLD) reported $177.9M in annual revenue (up from $205.1M in FY2024, -13.3% YoY) and -$58.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($153.4M revenue, -$49.4M net income) through FY2025, BOLD scaled operating cash flow to -$46.7M and free cash flow to -$47.2M, backed by $157.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 10/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.96 – $3.16 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore β€” Investors should note that the only sector context provided is the Health Care / Pharmaceutical Preparations classification and a beta of 1.0.

  • Key Question #1: Can BOLD sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $177.9M and free cash flow of -$47.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BOLD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BOLD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Boundless Bio Inc. (BOLD) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BOLD Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BOLD Bull vs. Bear Conversation Board β€” What's Your Call at $2.44?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BOLD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BOLD:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER β€’ Verified $100K Arena Trader πŸ‚ BULLISH 🎯 Target: $3.14 (+27.1%)
πŸ“Œ Pinned Debate

Forensic balance-sheet metrics (Altman Z 2.5, Debt/Equity 0.5) indicate the company is not in acute distress, and recent insider purcha

Forensic balance-sheet metrics (Altman Z 2.5, Debt/Equity 0.5) indicate the company is not in acute distress, and recent insider purchases were reported.. When you look under the hood at BOLD, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (10/20) has been quietly accumulating below $3.16. My 12M target is $3.14.

SectorRotator πŸ‚ BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER β€’ Accounting Quality Watch 🐻 BEARISH 🎯 Target: $2.03 (-17.8%)
Spot @ $2.47

The company reported negative operating income, net income, and free cash flow in every listed period, with ROIC at -35% and no reporte

Fading this rally in BOLD at $2.47. The company reported negative operating income, net income, and free cash flow in every listed period, with ROIC at -35% and no reported revenue.. With a beta of 1.0 and the stock sitting at $2.47 (52-wk range $0.96–$3.16), the easy multiple expansion is already priced in.

LIVE TAPE